ArticlePloS one2026
MoGraphDRP: Multi-omics and graph fusion with bilinear attention for predicting drug sensitivity.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Accurate prediction of drug response in cancer cells is a fundamental step toward achieving precision medicine and designing personalized therapies. In this study, a multi-branch deep learning framework is proposed that integrates multi-omics cellular data including gene expression, mutation, methylation, and biological pathways with structural features of drugs (molecular graphs and various chemical fingerprints) to enable drug response prediction. The graph structure of the drug is modeled using a three-layer Graph Convolutional Network (GCN), and chemical fingerprints are compressed using MLP networks. These multiple representations of drugs are integrated and then combined with cellular features in a Multi-head Bilinear Attention module to model the complex interactions between cells and drugs. In the final stage, an ensemble model based on XGBoost is used to refine the outputs. The MoGraphDRP model demonstrates significantly higher accuracy in drug response prediction compared to existing state-of-the-art methods. Experimental results show that the MoGraphDRP model outperforms advanced methods such as BANDRP, DeepCDR, and DeepTTA, achieving PCC = 0.9689, RMSE = 0.6622, and R² = 0.9388. This model not only accurately reconstructs missing IC50 values but also effectively distinguishes between sensitive and resistant drugs in unknown combinations. The MoGraphDRP framework can serve as a powerful, interpretable, and reliable tool for analyzing drug response and designing preclinical treatments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.